205110-48-1
Chemical Structure
Cethromycin
Synonym(s): ABT-773; Abbott-195773; A-195773
- CAS No.: 205110-48-1
- Formula:C42H59N3O10
- Molecular Weight:765.93
IUPAC Name: (3aS,4R,7R,9R,10R,11R,13R,15R,15aR)-10-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-4-ethyl-3a,7,9,11,13,15-hexamethyl-11-(((Z)-3-(quinolin-3-yl)allyl)oxy)octahydro-2H-[1]oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetraone
InChIKey: PENDGIOBPJLVBT-COVUKVLKSA-N
SMILES: O[C@H]1[C@@](O[C@@H]([C@@](OC/C=C\C2=CC(C=CC=C3)=C3N=C2)(C)C[C@@H](C)C4=O)[C@@H](C)C([C@@H](C)C(O[C@H](CC)[C@](OC(N5)=O)(C)[C@@]5([H])[C@H]4C)=O)=O)([H])O[C@H](C)C[C@@H]1N(C)C
Biological Activity: Cethromycin (ABT-773; Abbott-195773) is an orally effective ketolide antibiotic with broad-spectrum antibacterial activity. Cethromycin binds to domains II/V of the 23S rRNA of the 50S subunit, inhibiting bacterial protein synthesis. Cethromycin can accumulate in lung tissue, alveolar macrophages, epithelial lining fluid, and human polymorphonuclear leukocytes. Cethromycin exhibits potent in vitro activity against a variety of respiratory pathogens, including Mycoplasma pneumoniae. Cethromycin exhibits significant intracellular and pulmonary enrichment and anti-inflammatory effects against mycoplasma pneumonia in mouse models, improving airway obstruction and airway hyperresponsiveness. Cethromycin disrupts the apicoplast and reduces liver-stage parasite burden during the liver stage of Plasmodium berghei. Cethromycin can be used in research related to pneumonia, Staphylococcus aureus infection, gonorrhea, and malaria[1][2][3][4][5][6][7][8][9][10].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Cethromycin | 96.19% | Cethromycin (ABT-773; Abbott-195773) is an orally effective ketolide antibiotic with broad-spectrum antibacterial activity. Cethromycin binds to domains II/V of the 23S rRNA of the 50S subunit, inhibiting bacterial protein synthesis. Cethromycin can accumulate in lung tissue, alveolar macrophages, epithelial lining fluid, and human polymorphonuclear leukocytes. Cethromycin exhibits potent in vitro activity against a variety of respiratory pathogens, including Mycoplasma pneumoniae. Cethromycin exhibits significant intracellular and pulmonary enrichment and anti-inflammatory effects against mycoplasma pneumonia in mouse models, improving airway obstruction and airway hyperresponsiveness. Cethromycin disrupts the apicoplast and reduces liver-stage parasite burden during the liver stage of Plasmodium berghei. Cethromycin can be used in research related to pneumonia, Staphylococcus aureus infection, gonorrhea, and malaria. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Cethromycin-d6 | 96.10% | Cethromycin-d6 (ABT-773-d6; Abbott-195773-d6; A-195773-d6) is the d6-labeled Cethromycin (HY-19655). Cethromycin (ABT-773; Abbott-195773) is an orally effective ketolide antibiotic with broad-spectrum antibacterial activity. Cethromycin binds to domains II/V of the 23S rRNA of the 50S subunit, inhibiting bacterial protein synthesis. Cethromycin can accumulate in lung tissue, alveolar macrophages, epithelial lining fluid, and human polymorphonuclear leukocytes. Cethromycin exhibits potent in vitro activity against a variety of respiratory pathogens, including Mycoplasma pneumoniae. Cethromycin exhibits significant intracellular and pulmonary enrichment and anti-inflammatory effects against mycoplasma pneumonia in mouse models, improving airway obstruction and airway hyperresponsiveness. Cethromycin disrupts the apicoplast and reduces liver-stage parasite burden during the liver stage of Plasmodium berghei. Cethromycin can be used in research related to pneumonia, Staphylococcus aureus infection, gonorrhea, and malaria. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Hammerschlag MR, et al. Use of cethromycin, a new ketolide, for treatment of community-acquired respiratory infections. Expert opinion on investigational drugs. 2008 Mar;17(3):387-400.
- [2]. Pavlović D, et al. Discovery of 4''-ether linked azithromycin-quinolone hybrid series: influence of the central linker on the antibacterial activity. ACS medicinal chemistry letters. 2011 May 12;2(5):331-6.
- [3]. Sullivan DJ, et al. Discovery of Novel Liver-Stage Antimalarials through Quantum Similarity. PLoS One. 2015 May 7;10(5):e0125593.
- [4]. Bosnar M, et al. Cellular uptake and efflux of azithromycin, erythromycin, clarithromycin, telithromycin, and cethromycin. Antimicrobial agents and chemotherapy. 2005 Jun;49(6):2372-7.
- [5]. Parnham MJ. Immunomodulatory effects of antimicrobials in the therapy of respiratory tract infections. Curr Opin Infect Dis. 2005 Apr;18(2):125-31.
- [6]. Kim MK, et al. Bactericidal effect and pharmacodynamics of cethromycin (ABT-773) in a murine pneumococcal pneumonia model. Antimicrobial agents and chemotherapy. 2002 Oct;46(10):3185-92.
- [7]. Hu Y, et al. The antimicrobial activity of cethromycin against Staphylococcus aureus and compared with erythromycin and telithromycin. BMC microbiology. 2023 Apr 20;23(1):109. [Content Brief]
- [8]. Kennedy G, et al. Cethromycin pharmacokinetics and pharmacodynamics for single dose cure of Plasmodium berghei liver stages. Antimicrob Agents Chemother. 2025 Aug 6;69(8):e0021525.
- [9]. Ríos AM, et al. Impact of cethromycin (ABT-773) therapy on microbiological, histologic, immunologic, and respiratory indices in a murine model of Mycoplasma pneumoniae lower respiratory infection. Antimicrobial agents and chemotherapy. 2004 Aug;48(8):2897-904.
- [10]. Xuan D, et al. Pharmacokinetics of ABT-773, a new semi-synthetic ketolide in neutropenic lung-infected mice: a population approach. J Pharm Pharmacol. 2002 Jan;54(1):71-5.
